Meningitis Vaccine Given Accelerated Approval by FDA

Accelerated approval for Hiberix, a Haemophilus b Conjugate Vaccine, has been granted by the U.S. Food and Drug Administration, drug maker GlaxoSmithKline said Wednesday.

Hiberix was approved as a booster dose for use in children ages 15 months to 4 years old in order to protect them from invasive disease caused by Haemophilus influenzae type b (Hib), RTTNews reported.

Hib disease is an often serious and potentially deadly bacterial infection that can cause meningitis.

The FDA's accelerated approval is meant to help deal with a shortage in the United States of a vaccine to protect infants from Hib. GlaxoSmithKline said the vaccine should be available within several weeks, RTTNews reported.

More on This

• New meningitis shot could halt African epidemics
• Cheap new meningitis vaccine cuts cases in Africa
• Japan halts Pfizer, Sanofi vaccines after four die
• Meningitis Vaccine Given Accelerated Approval by FDA

Tags

• Meningitis

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Do you really want to post anonymously?

Are You a Member? Log InConnect your comment to your member profile. It only takes a second! Not a Member? Join Now!You'lll be automatically notified when someone else comments on your post.

Tell us what you think Write your comment here *

Leave this field blank

Receive email notifications of new comments Email Addresss

Sign me up for EmpowHER's FREE Newsletter!

Type in the characters above *

By hitting submit, you agree to EmpowHER's terms of service and privacy policy